1834 Investment Advisors Co. Has $6.62 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

1834 Investment Advisors Co. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 45,738 shares of the company's stock after selling 2,459 shares during the period. 1834 Investment Advisors Co.'s holdings in Johnson & Johnson were worth $6,615,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. Vinva Investment Management Ltd lifted its position in shares of Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock valued at $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. raised its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after purchasing an additional 9,309 shares during the last quarter. Meridian Investment Counsel Inc. lifted its position in Johnson & Johnson by 19.6% during the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after purchasing an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock valued at $2,858,543,000 after buying an additional 102,502 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $69,859,000. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wells Fargo & Company lowered their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Leerink Partners cut their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $170.44.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $1.72 during trading hours on Thursday, hitting $152.87. 2,045,698 shares of the company were exchanged, compared to its average volume of 9,333,421. The stock has a market capitalization of $368.05 billion, a price-to-earnings ratio of 22.98, a P/E/G ratio of 2.45 and a beta of 0.51. The business has a 50-day moving average of $147.73 and a 200-day moving average of $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the business posted $2.29 EPS. The company's revenue for the quarter was up 5.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.